D P Devanand1. 1. Psychiatry and Neurology, Geriatric Psychiatry, Columbia University Medical Center, New York, NY, 10032, USA. dpd3@cumc.columbia.edu.
Abstract
PURPOSE OF REVIEW: Viruses, particularly herpes simplex virus (HSV), may be a cause of Alzheimer's disease (AD). The evidence supporting the viral hypothesis suggests that antiviral treatment trials, which have not been conducted, are warranted. RECENT FINDINGS: HSV1 (oral herpes) and HSV2 (genital herpes) can trigger amyloid aggregation, and their DNA is common in amyloid plaques. HSV1 reactivation is associated with tau hyperphosphorylation and possibly tau propagation. Anti-HSV drugs reduce Aβ and p-tau accumulation in infected mouse brains. Clinically, after the initial oral infection, herpes simplex virus-1 (HSV1) becomes latent in the trigeminal ganglion and recurrent reactivation may produce neuronal damage and AD pathology. Clinical studies show cognitive impairment in HSV seropositive patients, and antiviral drugs show strong efficacy against HSV. An antiviral treatment trial in AD is clearly warranted. A phase II treatment trial with valacyclovir, an anti-HSV drug, recently began with evaluation of clinical and biomarker outcomes.
PURPOSE OF REVIEW: Viruses, particularly herpes simplex virus (HSV), may be a cause of Alzheimer's disease (AD). The evidence supporting the viral hypothesis suggests that antiviral treatment trials, which have not been conducted, are warranted. RECENT FINDINGS:HSV1 (oral herpes) and HSV2 (genital herpes) can trigger amyloid aggregation, and their DNA is common in amyloid plaques. HSV1 reactivation is associated with tau hyperphosphorylation and possibly tau propagation. Anti-HSV drugs reduce Aβ and p-tau accumulation in infectedmouse brains. Clinically, after the initial oral infection, herpes simplex virus-1 (HSV1) becomes latent in the trigeminal ganglion and recurrent reactivation may produce neuronal damage and AD pathology. Clinical studies show cognitive impairment in HSV seropositivepatients, and antiviral drugs show strong efficacy against HSV. An antiviral treatment trial in AD is clearly warranted. A phase II treatment trial with valacyclovir, an anti-HSV drug, recently began with evaluation of clinical and biomarker outcomes.
Authors: Fujie Xu; Maya R Sternberg; Benny J Kottiri; Geraldine M McQuillan; Francis K Lee; Andre J Nahmias; Stuart M Berman; Lauri E Markowitz Journal: JAMA Date: 2006-08-23 Impact factor: 56.272
Authors: Li Liu; Valerie Drouet; Jessica W Wu; Menno P Witter; Scott A Small; Catherine Clelland; Karen Duff Journal: PLoS One Date: 2012-02-01 Impact factor: 3.240
Authors: Roberta Mancuso; Francesca Baglio; Simone Agostini; Monia Cabinio; Maria M Laganà; Ambra Hernis; Nicolò Margaritella; Franca R Guerini; Milena Zanzottera; Raffaello Nemni; Mario Clerici Journal: Front Aging Neurosci Date: 2014-10-15 Impact factor: 5.750
Authors: Roberto Piacentini; Giovanna De Chiara; Domenica D Li Puma; Cristian Ripoli; Maria E Marcocci; Enrico Garaci; Anna T Palamara; Claudio Grassi Journal: Front Pharmacol Date: 2014-05-07 Impact factor: 5.810
Authors: D P Devanand; Howard Andrews; William C Kreisl; Qolamreza Razlighi; Anne Gershon; Yaakov Stern; Akiva Mintz; Thomas Wisniewski; Edward Acosta; Julianna Pollina; Mariasofia Katsikoumbas; Karen L Bell; Gregory H Pelton; Deborah Deliyannides; K M Prasad; Edward D Huey Journal: BMJ Open Date: 2020-02-06 Impact factor: 2.692